Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Inventory (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Inventory for 4 consecutive years, with $35234.0 as the latest value for Q3 2025.

  • On a quarterly basis, Inventory rose 38.92% to $35234.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $35234.0, a 38.92% increase, with the full-year FY2024 number at $27608.0, up 49.36% from a year prior.
  • Inventory was $35234.0 for Q3 2025 at bioAffinity Technologies, down from $43971.0 in the prior quarter.
  • In the past five years, Inventory ranged from a high of $43971.0 in Q2 2025 to a low of $5540.0 in Q4 2022.
  • A 4-year average of $20868.9 and a median of $18484.0 in 2023 define the central range for Inventory.
  • Peak YoY movement for Inventory: decreased 16.3% in 2024, then soared 308.79% in 2025.
  • bioAffinity Technologies' Inventory stood at $5540.0 in 2022, then soared by 233.65% to $18484.0 in 2023, then skyrocketed by 49.36% to $27608.0 in 2024, then rose by 27.62% to $35234.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Inventory are $35234.0 (Q3 2025), $43971.0 (Q2 2025), and $38782.0 (Q1 2025).